Accession Number: | 0001209191-20-013029 |
Date: | 2020-02-24 |
Issuer: | VERTEX PHARMACEUTICALS INC / MA (VRTX) |
Original Submission Date: |
LEIDEN JEFFREY M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON, MA 02210
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-02-24 | F | 8,410 | d | $239.23 | 103,131 | direct | ||
COMMON STOCK | 2020-02-25 | S | 2,273 | d | $229.77 | 100,858 | direct | ||
COMMON STOCK | 2020-02-25 | S | 1,120 | d | $230.40 | 99,738 | direct | ||
COMMON STOCK | 2020-02-25 | S | 1,050 | d | $231.76 | 98,688 | direct | ||
COMMON STOCK | 2020-02-25 | S | 1,017 | d | $232.96 | 97,671 | direct | ||
COMMON STOCK | 2020-02-25 | S | 1,640 | d | $234.49 | 96,031 | direct | ||
COMMON STOCK | 2020-02-25 | S | 1,210 | d | $235.53 | 94,821 | direct | ||
COMMON STOCK | 2020-02-25 | S | 560 | d | $236.63 | 94,261 | direct | ||
COMMON STOCK | 2020-02-25 | S | 1,680 | d | $238.33 | 92,581 | direct | ||
COMMON STOCK | 2020-02-24 | 0 | $0.00 | 440 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | transaction made pursuant to dr. leiden's company approved trading plan under rule 10b5-1. |
f2 | dr. leiden undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
f3 | open market sales reported on this line occurred at a weighted average price of $229.77 (range $229.07 to $230.00). |
f4 | open market sales reported on this line occurred at a weighted average price of $230.40 (range $230.14 to $230.73). |
f5 | open market sales reported on this line occurred at a weighted average price of $231.76 (range $231.27 to $232.14). |
f6 | open market sales reported on this line occurred at a weighted average price of $232.96 (range $232.27 to $233.11). |
f7 | open market sales reported on this line occurred at a weighted average price of $234.49 (range $233.99 to $234.66). |
f8 | open market sales reported on this line occurred at a weighted average price of $235.53 (range $235.07 to $235.72). |
f9 | open market sales reported on this line occurred at a weighted average price of $238.33 (range $238.16 to $238.56). |